Molecular mechanisms contributing to necrotizing enterocolitis

Annals of Surgery

Volumn 233, Issue 6, 2001, Pages 835-842

  Chung, Dai H ^a,b   Ethridge, Richard T ^a,b   Kim, Sunghoon ^a,b   Owens Stovall, Sharla ^a,b   Hernandez, Ambrosio ^a,b   Kelly, David R ^a,b   Evers, B Mark ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NECROTIZING ENTEROCOLITIS; NEWBORN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; SMALL INTESTINE; SUPERIOR MESENTERIC ARTERY OBSTRUCTION;

ANIMALS; BLOTTING, WESTERN; CYCLOOXYGENASE 2; ENTEROCOLITIS, NECROTIZING; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT, NEWBORN; INTESTINE, SMALL; ISOENZYMES; MEMBRANE PROTEINS; NF-KAPPA B; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS;

EID: 0034988440     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200106000-00014     Document Type: Conference Paper

References (33)

1. Necrotizing enterocolitis
2. Necrotizing enterocolitis of the newborn: Pathogenetic concepts in perspective
3. Necrotizing enterocolitis: A prospective multicenter investigation
4. Epidemiology of necrotizing enterocolitis
5. Necrotizing enterocolitis in full-term or near-term infants: Risk factors
6. Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin
7. Necrotizing enterocolitis
8. Arachidonic acid metabolism
9. Prostaglandin endoperoxide synthase: Why two isoforms?
10. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease
11. Interleukin-1 beta activates expression of cyclooxygenase-2 and inducible nitric oxide synthase in primary hippocampal neuronal culture: Platelet-activating factor as a preferential mediator of cyclooxygenase-2 expression
12. Interleukin-1 beta-induced cyclooxygenase-2 expression requires activation of both c-Jun NH2-terminal kinase and p38 MAPK signal pathways in rat renal mesangial cells
13. Differential regulation of cyclooxygenase 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts
14. Structure of the human cyclooxygenase-2 gene
15. NF-κB: A lesson in family values
16. NF-κB as a primary regulator of the stress response
17. Activation of nuclear factor κB in inflammatory bowel disease
18. NF-κB/Rel activation in cerulein pancreatitis
19. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
20. Inhibition of heat-shock protein 70 induction in intestinal cells overexpressing cyclooxygenase 2
21. Mitochondrial DNA damage and altered membrane potential (delta psi) in pancreatic acinar cells induced by reactive oxygen species
22. A model of intestinal ischemia in the neonatal rat utilizing superior mesenteric artery occlusion and intraluminal platelet-activating factor
23. Cyclooxygenase 1 and 2
24. 1 effect on human splanchnic circulation at different dose levels
25. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1
26. Prostaglandins in human milk
27. Selective inhibitors of cyclooxygenase-2: Are they really effective, selective, and GI-safe?
28. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2
29. Hypoxia induces cyclooxygenase-2 via the NF-κB p65 transcription factor in human vascular endothelial cells
30. Cyclooxygenase 2 (COX-2) gene activation is regulated by cyclic adenosine monophosphate
31. Inflammatory cytokines, nitric oxide, and necrotizing enterocolitis
32. Pyrrolidine dithiocarbamate protects mice from lethal shock induced by LPS or TNF-α
33. Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex